Skip to main content
OpenTrials

Clinical trial condition

Advanced Renal Cell Carcinoma

Explore clinical trials studying Advanced Renal Cell Carcinoma. Study availability and eligibility vary by location and protocol.

51 public trials 12 recruiting studies
Refine in advanced search Browse all conditions

Advanced Renal Cell Carcinoma trial results

Completed

Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

NCT03117309

Conditions
Advanced Renal Cell Carcinoma
Locations
  • Yale University, Yale Cancer Center New Haven, Connecticut, United States
  • Georgetown University Washington D.C., District of Columbia, United States
  • Winship Cancer Institute of Emory University Atlanta, Georgia, United States
  • Northwestern University Feinberg Schooll Of Medicine Chicago, Illinois, United States
View Trial Details
Completed

Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment

NCT03200717

Conditions
Adenocarcinoma, Advanced Renal Cell Carcinoma, Carcinoma, +15 more
Locations
  • Roswell Park Cancer Institute Buffalo, New York, United States
  • Novartis Investigative Site Caba, Buenos Aires, Argentina
  • Novartis Investigative Site Graz, Austria
  • Novartis Investigative Site Salzburg, Austria
View all 22 locations
View Trial Details
Completed

A Study to Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France.

NCT05444933

Conditions
Advanced Renal Cell Carcinoma
Locations
  • CHU Amiens Amiens, France
  • CHU Angers Angers, France
  • Institut Sainte Catherine Avignon, France
  • CHU Besançon Besançon, France
View all 28 locations
View Trial Details
Completed

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

NCT03428217

Conditions
Adenocarcinoma, Advanced Renal Cell Carcinoma, Carcinoma, +15 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Mayo Clinic Cancer Center Phoenix, Arizona, United States
  • The University of Arizona Cancer Center Tucson, Arizona, United States
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute Los Angeles, California, United States
View all 133 locations
View Trial Details
Completed

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

NCT01664182

Conditions
Adenocarcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, +17 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
View Trial Details
Completed

Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma

NCT01513187

Conditions
Advanced Renal Cell Carcinoma
Locations
  • Instituto Catalán de Oncología, Hospitalet del Llobregat L'Hospitalet de Llobregat, Barcelona, Spain
  • Centro Integral Oncológico Clara Campal PAU de Sanchinarro, Sanchinarro - Madrid, Spain
  • Hospital del Mar Barcelona, Spain
  • Hospital Clínic Barcelona, Spain
View all 13 locations
View Trial Details

Related conditions